Alltrna Unveils $109M to Make tRNA a Universal Therapy for Genetic Diseases
Flagship Pioneering-founded Alltrna is developing tRNA therapies to address genetic diseases driven by truncated versions of proteins. By addressing an aberrant genetic instruction underpinning many diseases, the startup is developing what it describes as a potential โuniversal solution.โ
United Kingdom United States Michelle Werner Tevard Biosciences American Society Of Cell Bristol Myers Squibb
Source: medcitynews.com